Antibodies positive for P.1 variants in LTC residents

Published Date: 16 Feb 2023

How is the SARS-CoV-2 mRNA antibody similar to the P.1 gamma strain and other strains?

Read Full News

Latest News

Game Changers: How Lorlatinib Shifts the Landscape

Dr Mark Kris breaks down why lorlatinib is a true game changer in ALK+ NSCLC, offering unprecedented 5-year PFS data alongside essential strategies to manage its unique toxicities.

FDA Psychiatry Roundup: June 2026

A monthly overview of FDA actions for psychiatric treatments and therapies.

CADe Succeeds in Real-World Colonoscopy QI Study

AI-based computer-aided detection devices during colonoscopy was associated with higher adenoma detection rates than usual care, a pragmatic, quality improvement trial shows.

Adjunctive Trauma Therapy May Help Improve Psychosis Care

Trauma-focused therapy is associated with reduced PTSD symptom severity and increased remission in patients with co-occurring psychosis, a new randomized trial shows.

Urologist Wins $6.8 Million in Damages in Retaliation Case

A Missouri urologist sued her employer, claiming the health system fired her after she complained about discrimination and harassment.

APOL1 Status May Refine Long-Term Kidney Donor Risk

High-risk APOL1 genotypes are associated with greater long-term kidney dysfunction among Black living donors, suggesting a potential role for genetic screening during donor evaluation.

Todays Updates

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

Todays Updates

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

Latest News

Dr Mark Kris breaks down why lorlatinib is a true game changer in ALK+ NSCLC, offering unprecedented 5-year PFS data alongside essential strategies to manage its unique toxicities.

A monthly overview of FDA actions for psychiatric treatments and therapies.

AI-based computer-aided detection devices during colonoscopy was associated with higher adenoma detection rates than usual care, a pragmatic, quality improvement trial shows.

Trauma-focused therapy is associated with reduced PTSD symptom severity and increased remission in patients with co-occurring psychosis, a new randomized trial shows.

A Missouri urologist sued her employer, claiming the health system fired her after she complained about discrimination and harassment.

High-risk APOL1 genotypes are associated with greater long-term kidney dysfunction among Black living donors, suggesting a potential role for genetic screening during donor evaluation.

News All Time

Is Alzheimer’s Research Focusing on the Wrong Target?

Antiamyloid drugs clear amyloid plaques and modestly slow cognitive decline in patients with Alzheimer’s disease, but whether the therapies produce meaningful clinical benefit is up for debate.

Painful Stump Ischemia in a Man After Amputation

A man with a prior below-knee amputation develops progressive stump pain, and vascular imaging reveals an unexpected arterial blockage that is still treatable.

Before Automating Healthcare, Define What to Automate

What belongs to medicine, and what belongs to the machine? Dr Travis Bias argues that AI must augment — not replace — human connection in clinical care.

Ask About Her Job: Medicine’s Missing Question

Dr Raghda Rashad argues that screening for occupational history could keep more women in the workforce, but most clinicians never ask.

Improving GAD Screening: What the GAD-7 May Miss

Dr Lily Brown explains why GAD is often underdiagnosed and how overreliance on depression labels and the GAD-7 alone can miss key anxiety disorders.

Extreme Heat: Is Health Toll Worse Than We Think?

Extreme heat is already increasing deaths, worsening chronic diseases, and widening health inequalities, as clinicians face growing pressure to prepare for a hotter future.

Clinical Connections May Tie Headaches and Obesity Together

Patients may not know it, but obesity can lead to more headaches.

Some Sleep Apnea Patients Benefit the Most From Tirzepatide

The weight-loss drug is approved to treat obstructive sleep apnea, but some types of patients seem to benefit the most.

Telitacicept Tames Proteinuria in IgA Nephropathy

Data from the first stage of a phase 3 study show significant reductions in proteinuria among patients treated with telitacicept.

Fathers’ Childhood Trauma Linked to Child Behavior Problems

Fathers’ adverse childhood experiences are linked to a higher likelihood of their children having behavior problems.

Lead and Mercury Levels Drop Markedly in UK Pregnancy

Blood lead and mercury levels fall markedly among pregnant women in the UK since the early 1990s, and methylmercury accounts for most mercury detected in the blood.

Social Needs Screening Not Associated With Use of Services

Social needs intervention in US pediatric practices is associated with higher rates of self-reported social needs discussions and referrals but not higher resource enrollment.

Professional Corner: Resident Well-Being, Maternity, & More

New study finds nearly 10% of internal medicine residents report a disability; the American Medical Association updates maternity care billing codes; and Texas joins autism trial network.

Venetoclax-Obinutuzumab Boosts MRD Clearance in CLL

A phase 3 trial compares first-line fixed-duration venetoclax-obinutuzumab to fludarabine, cyclophosphamide, and rituximab/bendamustine-rituximab in patients with CLL.

Low-Dose Atropine for Childhood Myopia: Worth Using?

A UK trial finds that low-dose atropine modestly slows childhood myopia progression and axial eye growth over 2 years without increasing adverse events.

Functional Cure for Hepatitis B Is Now ‘Achievable’

Bepirovirsen reduced posttreatment markers of hepatitis B infection at 72 weeks, with 20% of recipients achieving functional cure vs none given placebo.